Premium
Single‐Molecule Bioelectronic Label‐Free Assay of both Protein and Genomic Markers of Pancreatic Mucinous Cysts’ in Whole Blood Serum
Author(s) -
Macchia Eleonora,
Sarcina Lucia,
Driescher Caroline,
Gounani Zahra,
Tewari Amit,
Osterbacka Ronald,
Palazzo Gerardo,
Tricase Angelo,
Kovacs Vajna Zsolt Miklos,
Viola Fabrizio,
Modena Francesco,
Caironi Mario,
Torricelli Fabrizio,
Esposito Irene,
Torsi Luisa
Publication year - 2021
Publication title -
advanced electronic materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.25
H-Index - 56
ISSN - 2199-160X
DOI - 10.1002/aelm.202100304
Subject(s) - kras , pancreatic cancer , cytology , cyst , fine needle aspiration , medicine , biology , blood test , cancer research , cancer , pathology , oncology , biopsy , colorectal cancer
The timely diagnosis of cystic pancreatic cancer precursors is of utmost importance to improve patients’ low survival rate. Fine‐needle aspiration cytology is endowed with low diagnostic sensitivity, while more effective is the assay of markers, such as a mutated KRAS , in the cyst fluids. Next‐generation sequencing, detecting down to a single copy of a genomic marker, enables early diagnosis but the diagnostic sensitivity of high‐grade cysts, likely to become malignant, is low. Assaying both mutated KRAS and MUC1 protein markers can improve diagnostic accuracy. Their detection in blood would also be minimally invasive. Here, the mucinous lesions markers, KRAS and MUC1, are both successfully assayed in blood serum at the physical limit with the label‐free “Single‐Molecule assay with a large Transistor—SiMoT.” This is a compelling proof of principle that the SiMoT platform holds high potential to enable a timely, minimally invasive, and accurate diagnosis of pancreatic cancer precursor cysts.